Medios AG: management transactions · Germany · BaFin

About Medios AG

Medios AG is a healthcare and specialty pharma company listed in Germany, with shares traded on Xetra/Frankfurt (DAX/MDAX/SDAX). For French-speaking investors, it is best understood as a leading European specialty-pharma platform focused on complex medicines and individualized therapies. Medios describes itself as Germany’s first listed specialty pharmaceutical company, and its registered office is in Berlin, Germany. ([medios.ag](https://medios.ag/en/news-detail-view/medios-ag-records-further-revenue-growth-in-the-first-quarter-of-2024-and/64?cHash=c659e5e08276107feb799b69126e2ee7&utm_source=openai)) The group’s business model is built around specialty pharmaceutical supply and patient-specific compounding. In practical terms, Medios serves pharmacies, specialist medical practices, and pharmaceutical companies, helping make innovative therapies available in areas such as rare, chronic, or highly individualized treatments. This business requires strict regulatory compliance, reliable cold-chain and logistics capabilities, and deep know-how in the handling of high-complexity pharmaceutical products. ([medios.ag](https://medios.ag/en/news-detail-view/medios-ag-records-further-revenue-growth-in-the-first-quarter-of-2024-and/64?cHash=c659e5e08276107feb799b69126e2ee7&utm_source=openai)) From a historical perspective, Medios developed in Germany as a focused specialty-pharma specialist and has since broadened its footprint through M&A. A major inflection point came in 2024 with the completion of the acquisition of Ceban Pharmaceuticals, which expanded Medios’ reach into the Netherlands, Belgium, and Spain through a fast-growing compounding platform. That transaction materially strengthened the company’s European market position and increased its scale in a still-fragmented niche. ([medios.ag](https://medios.ag/en/news-detail-view/medios-ag-successfully-completes-acquisition-of-ceban-significantly-expanding/64?cHash=c659e5e08276107feb799b69126e2ee7&utm_source=openai)) Geographically, Medios remains firmly anchored in Germany, but it now operates on a more international European basis. Its core markets benefit from growing demand for personalized medicine, secure specialty-drug supply, and outsourced pharmaceutical services. Medios’ competitive edge comes from combining distribution, compounding, and pharmaceutical expertise in one integrated platform, which differentiates it from a standard wholesaler. ([medios.ag](https://medios.ag/en/news-detail-view/medios-ag-successfully-completes-acquisition-of-ceban-significantly-expanding/64?cHash=c659e5e08276107feb799b69126e2ee7&utm_source=openai)) Recent company developments point to continued operational momentum. In 2025, Medios reported improving profitability and cash flow in interim results and reaffirmed its full-year outlook. The company also announced that Thomas Meier will take over as CEO on February 1, 2026. In addition, Medios executed and successfully completed a public share buyback offer in 2025, which signals management confidence and supports the capital-allocation story. ([medios.ag](https://medios.ag/newsdetailview/medios-ag-erzielt-kraeftiges-wachstum-von-ergebnis-und-ergebnismarge-im/50?cHash=b4dc1085513752733b2ed16edc8be503&utm_source=openai))